Osteoclast Immunosuppressive Effects in Multiple Myeloma: Role of Programmed Cell Death Ligand 1

Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway

(2018) Dandan Chen et al.   CELL CYCLE

Isatuximab plus pomalidomide/dexamethasone versus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma: ICARIA Phase III study design

(2018) Paul G Richardson et al.   Future Oncology

Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline Update

(2018) Kenneth Anderson et al.   JOURNAL OF CLINICAL ONCOLOGY

Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway

(2018) Rosemarie Tremblay-LeMay et al.   Journal of Hematology & Oncology

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

(2018) Noopur Raje et al.   LANCET ONCOLOGY

Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma

(2018) María-Victoria Mateos et al.   NEW ENGLAND JOURNAL OF MEDICINE

RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer

(2018) Elizabeth Ahern et al.   OncoImmunology

IL21R expressing CD14 + CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclasts

(2017) Marina Bolzoni et al.   HAEMATOLOGICA

Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation

(2017) Nathan De Beule et al.   JOURNAL OF PATHOLOGY

Combination of a novel HDAC6 inhibitor ACY-241 and anti-PD-L1 antibody enhances anti-tumor immunity and cytotoxicity in multiple myeloma

(2017) A Ray et al.   LEUKEMIA

Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy

(2017) K R Kelly et al.   LEUKEMIA

Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu

(2017) L Zhang et al.   Blood Cancer Journal

Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation

(2017) Federica Costa et al.   Oncotarget

Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression

(2017) Massimo Giuliani et al.   Oncotarget

IL21R expressing CD14 + CD16 + monocytes expand in multiple myeloma patients leading to increased osteoclasts

(2017) Marina Bolzoni et al.   HAEMATOLOGICA

Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs

(2017) Gianfranco Pittari et al.   Frontiers in Immunology

Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication

(2016) G. An et al.   BLOOD

APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment

(2016) Y.-T. Tai et al.   BLOOD

Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

(2016) Jacalyn Rosenblatt et al.   BLOOD

Immune Therapies in Multiple Myeloma

(2016) Shaji K. Kumar et al.   CLINICAL CANCER RESEARCH

Inflammatory Osteoclasts Prime TNFα-Producing CD4+T Cells and Express CX3CR1

(2016) Lidia Ibáñez et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Multiple myeloma–derived MMP-13 mediates osteoclast fusogenesis and osteolytic disease

(2016) Jing Fu et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Osteoclast-Primed Foxp3+CD8 T Cells Induce T-bet, Eomesodermin, and IFN-γ To Regulate Bone Resorption

(2016) Elena V. Shashkova et al.   JOURNAL OF IMMUNOLOGY

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

Myeloma Drug Resistance Induced by Binding of Myeloma B7-H1 (PD-L1) to PD-1

(2016) M. Ishibashi et al.   Cancer Immunology Research

Immunotherapies targeting CD38 in Multiple Myeloma

(2016) Djordje Atanackovic et al.   OncoImmunology

Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathy

(2015) M. V. Dhodapkar et al.   BLOOD

IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer

(2015) K Abiko et al.   BRITISH JOURNAL OF CANCER

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma

(2015) G. Gorgun et al.   CLINICAL CANCER RESEARCH

Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future

(2015) Lieping Chen et al.   JOURNAL OF CLINICAL INVESTIGATION

SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide

(2015) H Jiang et al.   LEUKEMIA

Targeting PD1–PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells

(2015) A Ray et al.   LEUKEMIA

The expression status and prognostic significance of programmed cell death 1 ligand 1 in gastro­intestinal tract cancer: a systematic review and meta-analysis

(2015) Xia Zhang et al.   OncoTargets and Therapy

Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche

(2015) Michelle A. Lawson et al.   Nature Communications

Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients

(2015) S Yousef et al.   Blood Cancer Journal

Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma

(2015) Liang Wang et al.   Oncotarget

PD-L1 and Survival in Solid Tumors: A Meta-Analysis

(2015) Pin Wu et al.   PLoS One

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy

(2015) Anne-Marit Sponaas et al.   PLoS One

LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease

(2015) Giacomina Brunetti et al.   Oncotarget

FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4+ T regulatory cells

(2014) Walter Moises Tobias Braga et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Inducible Expression of B7-H1 (PD-L1) and Its Selective Role in Tumor Site Immune Modulation

(2014) Miguel F. Sanmamed et al.   CANCER JOURNAL

Targeting the bone marrow microenvironment in multiple myeloma

(2014) Yawara Kawano et al.   IMMUNOLOGICAL REVIEWS

IL-10: The Master Regulator of Immunity to Infection

(2014) Kevin N. Couper et al.   JOURNAL OF IMMUNOLOGY

A novel Bruton’s tyrosine kinase inhibitor CC-292 in combination with the proteasome inhibitor carfilzomib impacts the bone microenvironment in a multiple myeloma model with resultant antimyeloma activity

(2014) H Eda et al.   LEUKEMIA

PD-1–PD-L1 axis: efficient checkpoint blockade against cancer

(2014) Alessia Errico   Nature Reviews Clinical Oncology

Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

(2014) Lotfi Benboubker et al.   NEW ENGLAND JOURNAL OF MEDICINE

T Cell Costimulation Molecules CD80/86 Inhibit Osteoclast Differentiation by Inducing the IDO/Tryptophan Pathway

(2014) A. Bozec et al.   Science Translational Medicine

Bone and the Innate Immune System

(2014) Julia F. Charles et al.   Current Osteoporosis Reports

Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans

(2013) G. T. Gorgun et al.   BLOOD

Osteoclast-induced Foxp3+ CD8 T-cells limit bone loss in mice

(2013) Zachary S. Buchwald et al.   BONE

Immunological Reaction in TNF-α-Mediated Osteoclast Formation and Bone ResorptionIn VitroandIn Vivo

(2013) Hideki Kitaura et al.   Clinical & Developmental Immunology

Programmed Death Receptor-1/Programmed Death Receptor Ligand-1 Blockade after Transient Lymphodepletion To Treat Myeloma

(2013) T. J. Kearl et al.   JOURNAL OF IMMUNOLOGY

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications

(2013) Y-T Tai et al.   LEUKEMIA

Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state

(2013) James Favaloro et al.   LEUKEMIA & LYMPHOMA

Annexin II interactions with the annexin II receptor enhance multiple myeloma cell adhesion and growth in the bone marrow microenvironment

(2012) S. D'Souza et al.   BLOOD

Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma

(2012) Y.-T. Tai et al.   BLOOD

Bone Marrow Stromal Cells Create a Permissive Microenvironment for Myeloma Development: A New Stromal Role for Wnt Inhibitor Dkk1

(2012) J. A. Fowler et al.   CANCER RESEARCH

Molecular Pathways: Next-Generation Immunotherapy--Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

(2012) D. S. Chen et al.   CLINICAL CANCER RESEARCH

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

(2012) David W. Dempster et al.   CLINICAL THERAPEUTICS

Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules

(2012) Marina Bolzoni et al.   EXPERIMENTAL HEMATOLOGY

Denosumab: mechanism of action and clinical outcomes

(2012) D. A. Hanley et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Osteoclasts promote the formation of hematopoietic stem cell niches in the bone marrow

(2012) Anna Mansour et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Marrow stromal cells induce B7-H1 expression on myeloma cells, generating aggressive characteristics in multiple myeloma

(2012) H Tamura et al.   LEUKEMIA

Osteoclast Activated FoxP3+ CD8+ T-Cells Suppress Bone Resorption in vitro

(2012) Zachary S. Buchwald et al.   PLoS One

Soluble Rank Ligand Produced by Myeloma Cells Causes Generalised Bone Loss in Multiple Myeloma

(2012) Clive Henry Buckle et al.   PLoS One

Osteoclasts in Multiple Myeloma Are Derived from Gr-1+CD11b+Myeloid-Derived Suppressor Cells

(2012) Junling Zhuang et al.   PLoS One

Immunosuppressive Effects of Multiple Myeloma Are Overcome by PD-L1 Blockade

(2011) William H.D. Hallett et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease

(2011) S. D'Souza et al.   BLOOD

Advances in the Biology and Treatment of Bone Disease in Multiple Myeloma

(2011) Noopur Raje et al.   CLINICAL CANCER RESEARCH

Immature dendritic cells from patients with multiple myeloma are prone to osteoclast differentiation in vitro

(2011) Marco Tucci et al.   EXPERIMENTAL HEMATOLOGY

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: Reduction post-bortezomib monotherapy

(2011) Evangelos Terpos et al.   INTERNATIONAL JOURNAL OF CANCER

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Increased bone density and resistance to ovariectomy-induced bone loss in FoxP3-transgenic mice based on impaired osteoclast differentiation

(2010) Mario M. Zaiss et al.   ARTHRITIS AND RHEUMATISM

Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration

(2010) J. Moreaux et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells

(2010) H. Li et al.   BLOOD

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody

(2010) D. M. Benson et al.   BLOOD

RANKL-independent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II

(2010) F. Hemingway et al.   BONE

The PD-1 pathway in tolerance and autoimmunity

(2010) Loise M. Francisco et al.   IMMUNOLOGICAL REVIEWS

IL-1 plays an important role in the bone metabolism under physiological conditions

(2010) Y.-M. Lee et al.   INTERNATIONAL IMMUNOLOGY

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

(2010) David E. Hughes et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease

(2010) S. Vallet et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Bone Damage in Rheumatoid Arthritis: Mechanistic Insights and Approaches to Prevention

(2010) Sougata Karmakar et al.   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Increased Level of both CD4+FOXP3+ Regulatory T Cells and CD14+HLA-DR−/low Myeloid-Derived Suppressor Cells and Decreased Level of Dendritic Cells in Patients with Multiple Myeloma

(2010) M. K. Brimnes et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor

(2009) Anne Catherine Sprynski et al.   BLOOD

Bortezomib induces osteoblast differentiation via Wnt-independent activation of  -catenin/TCF signaling

(2009) Y.-W. Qiang et al.   BLOOD

Osteoclasts are important for bone angiogenesis

(2009) F. C. Cackowski et al.   BLOOD

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma

(2009) E. Jost et al.   CANCER LETTERS

PD-1 signaling in primary T cells

(2009) James L. Riley   IMMUNOLOGICAL REVIEWS

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Cross-Presentation by Osteoclasts Induces FoxP3 in CD8+ T Cells

(2009) J. R. Kiesel et al.   JOURNAL OF IMMUNOLOGY

International myeloma working group consensus statement and guidelines regarding the current role of imaging techniques in the diagnosis and monitoring of multiple Myeloma

(2009) M Dimopoulos et al.   LEUKEMIA

CTLA-4 directly inhibits osteoclast formation

(2008) R Axmann et al.   ANNALS OF THE RHEUMATIC DISEASES

Clinical, Radiographic, and Biochemical Characterization of Multiple Myeloma Patients with Osteonecrosis of the Jaw

(2008) N. Raje et al.   CLINICAL CANCER RESEARCH

Osteoimmunology: Interactions of the Bone and Immune System

(2008) Joseph Lorenzo et al.   ENDOCRINE REVIEWS

CD137L- and RANKL-mediated reverse signals inhibit osteoclastogenesis and T lymphocyte proliferation

(2008) Ramamoorthy Senthilkumar et al.   IMMUNOBIOLOGY

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*

(2008) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice

(2008) Siddhartha Mukherjee et al.   JOURNAL OF CLINICAL INVESTIGATION

Effect of pathologic fractures on survival in multiple myeloma patients: a case control study

(2008) Mehmet Sonmez et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma

(2008) I Breitkreutz et al.   LEUKEMIA

Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6

(2008) Huang Hongming et al.   LEUKEMIA RESEARCH

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

The PD-1/PD-L costimulatory pathway critically affects host resistance to the pathogenic fungus Histoplasma capsulatum

(2008) E. Lazar-Molnar et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu

(2007) Y.-T. Tai et al.   BLOOD